|
Date |
Name |
Title |
Volume |
Trade Price |
Holding Change |
|
5/22/2013
|
FERRARI LOUIS
|
President and CEO
|
-1,020
|
$0.57
|
-0.33%
|
|
4/30/2013
|
Bahrt Kenneth
|
SVP, Chief Medical Officer
|
-1,250
|
$0.74
|
-0.70%
|
|
4/30/2013
|
CROWLEY Richard
|
EVP, Chief Operating Officer
|
-2,485
|
$0.74
|
-0.86%
|
|
3/6/2013
|
Gionco David
|
Group VP & Chief Acct. Officer
|
-1,560
|
$0.93
|
-1.83%
|
|
2/25/2013
|
FERRARI LOUIS
|
President and CEO
|
-375
|
$0.99
|
-0.13%
|
|
2/4/2013
|
YACHMETZ PHILIP K
|
SVP, General Counsel
|
-3,203
|
$1.02
|
-1.04%
|
|
2/4/2013
|
YACHMETZ PHILIP K
|
SVP, General Counsel
|
-27,297
|
$1.01
|
-8.17%
|
|
2/4/2013
|
FERRARI LOUIS
|
President and CEO
|
-3,200
|
$1.02
|
-1.07%
|
|
2/4/2013
|
FERRARI LOUIS
|
President and CEO
|
-59,000
|
$1.01
|
-16.45%
|
|
2/4/2013
|
CROWLEY Richard
|
EVP, Biopharmaceutical Ops
|
-30,000
|
$1.05
|
-9.43%
|
|
2/4/2013
|
CROWLEY Richard
|
EVP, Biopharmaceutical Ops
|
-18,900
|
$1.01
|
-5.61%
|
|
2/4/2013
|
Bahrt Kenneth
|
SVP, Chief Medical Officer
|
-21,700
|
$1.04
|
-11.22%
|
|
2/4/2013
|
Bahrt Kenneth
|
SVP, Chief Medical Officer
|
-7,300
|
$1.01
|
-3.64%
|
|
1/31/2013
|
Bahrt Kenneth
|
SVP, Chief Medical Officer
|
-1,300
|
$1.03
|
-0.64%
|
|
1/31/2013
|
CROWLEY Richard
|
EVP, Biopharmaceutical Ops
|
-2,415
|
$1.02
|
-0.71%
|
|
1/14/2013
|
YACHMETZ PHILIP K
|
SVP, General Counsel
|
-1,283
|
$1.14
|
-0.38%
|
|
11/26/2012
|
FERRARI LOUIS
|
President and CEO
|
-950
|
$1.16
|
-0.26%
|
|
10/31/2012
|
CROWLEY Richard
|
EVP, Biopharmaceutical Ops
|
-2,010
|
$1.45
|
-0.59%
|
|
10/31/2012
|
Bahrt Kenneth
|
SVP, Chief Medical Officer
|
-1,000
|
$1.45
|
-0.49%
|
|
8/22/2012
|
FERRARI LOUIS
|
President and CEO
|
-984
|
$1.00
|
-0.28%
|
|
8/2/2012
|
CROWLEY Richard
|
EVP, Biopharma Operatiotions
|
-2,500
|
$0.62
|
-0.73%
|
|
8/1/2012
|
Bahrt Kenneth
|
SVP, Chief Medical Officer
|
-4,950
|
$0.62
|
-2.38%
|
|
5/22/2012
|
Constantine Ginger
|
Director
|
49,382
|
$0.81
|
315.88%
|
|
5/22/2012
|
THOMPSON VIRGIL
|
Director
|
49,382
|
$0.81
|
82.04%
|
|
5/22/2012
|
Owen William F
|
Director
|
49,382
|
$0.81
|
681.22%
|
|
5/22/2012
|
JAEGER STEPHEN O
|
Director
|
98,765
|
$0.81
|
148.20%
|
|
5/22/2012
|
FERRARI LOUIS
|
EVP, North American Commerical
|
-942
|
$0.82
|
-0.27%
|
|
5/1/2012
|
CROWLEY Richard
|
EVP Biopharmaceutical Operatio
|
-9,200
|
$2.35
|
-2.61%
|
|
2/27/2012
|
YACHMETZ PHILIP K
|
SVP, General Counsel
|
100,000
|
$2.10
|
42.47%
|
|
2/22/2012
|
FERRARI LOUIS
|
EVP, North American Commerical
|
-4,100
|
$2.06
|
-1.16%
|
|
2/14/2012
|
YACHMETZ PHILIP K
|
SVP, General Counsel
|
-3,540
|
$2.02
|
-1.48%
|
|
2/1/2012
|
FERRARI LOUIS
|
EVP, N American Commerical Ops
|
310,000
|
$2.26
|
695.02%
|
|
2/1/2012
|
YACHMETZ PHILIP K
|
SVP, General Counsel
|
50,000
|
$2.26
|
26.45%
|
|
2/1/2012
|
CROWLEY Richard
|
EVP, Biopharmaceutical Ops
|
250,000
|
$2.26
|
242.72%
|
|
2/1/2012
|
Bahrt Kenneth
|
SVP, Chief Medical Officer
|
150,000
|
$2.26
|
258.62%
|
|
11/30/2011
|
FERRARI LOUIS
|
EVP, N American Commerical Ops
|
381
|
$2.13
|
0.86%
|
|
11/21/2011
|
FERRARI LOUIS
|
SVP, North American Commerical
|
4,000
|
$2.29
|
10.00%
|
|
11/21/2011
|
CROWLEY Richard
|
EVP Biopharmaceutical Operatio
|
3,000
|
$2.53
|
3.00%
|
|
11/21/2011
|
JOHNSON JOHN
|
CEO & President
|
5,000
|
$2.30
|
1.89%
|
|
11/18/2011
|
JOHNSON JOHN
|
CEO & President
|
10,000
|
$2.28
|
3.92%
|
|
11/18/2011
|
JOHNSON JOHN
|
CEO & President
|
1,000
|
$2.36
|
33.33%
|
|
11/18/2011
|
ZUERBLIS KENNETH J
|
EVP, Chief Financial Officer
|
2,000
|
$2.35
|
40.00%
|
|
11/16/2011
|
Bahrt Kenneth
|
SVP, Chief Medical Officer
|
5,000
|
$2.59
|
9.43%
|
|
9/16/2011
|
YACHMETZ PHILIP K
|
SVP, General Counsel
|
7,000
|
$4.13
|
3.85%
|
|
9/16/2011
|
JOHNSON JOHN
|
CEO & President
|
1,500
|
$4.09
|
100.00%
|
|
9/16/2011
|
JOHNSON JOHN
|
CEO & President
|
25,000
|
$4.10
|
10.87%
|
|
9/15/2011
|
ZUERBLIS KENNETH J
|
EVP, Chief Financial Officer
|
4,000
|
$4.05
|
400.00%
|
|
9/15/2011
|
HELLER ALAN L
|
Director
|
7,500
|
$3.99
|
22.95%
|
|
9/14/2011
|
Bahrt Kenneth
|
SVP, Chief Medical Officer
|
500
|
$3.97
|
0.95%
|
|
9/14/2011
|
Bahrt Kenneth
|
SVP, Chief Medical Officer
|
2,500
|
$3.95
|
5.00%
|
|
8/31/2011
|
FERRARI LOUIS
|
EVP, N American Commerical Ops
|
222
|
$3.66
|
0.50%
|
|
7/31/2011
|
Bahrt Kenneth
|
SVP, Chief Medical Officer
|
-50,000
|
$7.00
|
-50.00%
|
|
5/26/2011
|
Constantine Ginger
|
Director
|
5,291
|
$7.78
|
51.16%
|
|
5/26/2011
|
JAEGER STEPHEN O
|
Director
|
10,582
|
$7.78
|
18.88%
|
|
5/26/2011
|
HELLER ALAN L
|
Director
|
5,291
|
$7.78
|
19.32%
|
|
5/26/2011
|
THOMPSON VIRGIL
|
Director
|
5,291
|
$7.78
|
9.64%
|
|
5/26/2011
|
Simon Lee S
|
Director
|
5,291
|
$7.78
|
22.15%
|
|
4/30/2011
|
CROWLEY Richard
|
EVP Biopharmaceutical Operatio
|
-100,000
|
$11.62
|
-50.00%
|
|
2/14/2011
|
Hamelin Paul
|
President
|
-5,371
|
$9.89
|
-4.13%
|
|
2/14/2011
|
YACHMETZ PHILIP K
|
SVP, General Counsel
|
-3,210
|
$9.88
|
-1.73%
|
|
1/24/2011
|
Gionco David
|
Group VP & CFO
|
-2,032
|
$10.00
|
-4.54%
|